SCHEMBL14720724

SCHEMBL14720724

CCOC(=O)c1ccc(C=C2CCN(C3CCCC3)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
POLB P06746 1/20 0.58
SMN1; SMN2 Q16637 2/20 0.48
MAPK1 P28482 2/20 0.46
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
FDFT1 P37268 1/20 0.44
SRD5A2 P31213 1/20 0.43
HTT P42858 2/20 0.43
HPGD P15428 1/20 0.43
MAPT P10636 2/20 0.42
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
OGFRL1 Q5TC84 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
ESR1 P03372 1/20 0.41
CA7 P43166 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14720551 0.98 ALDH1A1 (0.56) ALDH1A1POLBSMN1; SMN2MAPK1RAB9A
SCHEMBL14721158 0.85 ALDH1A1 (0.43) ALDH1A1POLBSMN1; SMN2MAPK1RAB9A
SCHEMBL14720485 0.81 ALDH1A1 (0.54) ALDH1A1POLBSMN1; SMN2MAPK1RAB9A
SCHEMBL10394369 0.81 CA12 (0.51) ALDH1A1SMN1; SMN2RAB9ANPC1HTT
SCHEMBL14721409 0.80 MAPK1 (0.41) ALDH1A1POLBMAPK1RAB9ANPC1
SCHEMBL14720729 0.80 SRD5A2 (0.47) ALDH1A1SMN1; SMN2RAB9ANPC1SRD5A2
SCHEMBL14720748 0.79 CA12 (0.44) ALDH1A1SMN1; SMN2MAPK1RAB9ANPC1
SCHEMBL14720720 0.78 SRD5A2 (0.58) ALDH1A1SRD5A2HTTHPGDMAPT
SCHEMBL14720484 0.78 ALDH1A1 (0.58) ALDH1A1POLBSMN1; SMN2MAPK1RAB9A
SCHEMBL6135228 0.78 ALDH1A1 (0.67) ALDH1A1POLBSMN1; SMN2MAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013027001-A1 COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 WO disclosed
WO-2013027001-A1 COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 WO disclosed